Investigation of the applicability of dry powder inhalation in patients with Parkinson*s disease.

Investigation of the applicability of dry powder inhalation in patients with Parkinson*s disease. - Dry powder inhalation in patients with Parkinson*s disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38957

Enrollment

Registered

2013-12-18

Start date

2014-04-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsons disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Predictable off periods. Recognizable off periods for themselves and others. At least 2 years of levodopa use. Signed informed consent. Diagnosed with Parkinson*s disease Age 18 or older.

Exclusion criteria

Exclusion criteria: Cognitive dysfunction, which precludes good understanding of instructions and/or informed consent. Current treatment with apomorphine or duodopa by pump. Any active pulmonary disease.

Design outcomes

Primary

Measure	Time frame
the main study parameter is the ability of a Parkinsons patient to use the inhaler correctly during off periods. The parameter that describes whether or not a Parkinsons patient is capable of using the inhaler correctly is the pressure drop (s)he creates over the inhaler upon inhalation. For the Twincer* a pressure drop of at least 2 kPa is needed, but the target pressure drop is 4 kPa.	—

Countries

Netherlands

Outcome results